News | February 25, 2023
EMA recommends refusal of the marketing authorization for Lagevrio
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Based on a post hoc analysis, fewer required respiratory interventions
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Subscribe To Our Newsletter & Stay Updated
